Peter R. Galle, MD, PhD

Durvalumab with or without Bevacizumab as Adjuvant Therapy for Patients with Hepatocellular Carcinoma at Risk of Recurrence After Curative Therapy: EMERALD-2

Purpose: Hepatic resection and ablation are standard of care for patients with hepatocellular carcinoma (HCC), but although potentially curative, the risk of recurrence is high (44%–79% a...

Joong-Won Park ;

Peter R. Galle , MD, PhD;

Riccardo Lencioni , MD;

Jennifer J. Knox ;

Jiaqi Fan , MD;

Ann-Lii Cheng , MD, PhD;

Shethah Morgan ;

Jian Zhou , MD, PhD;

Sean Cleary ;

Norihiro Kokudo ;

10/21/2019

O-021: Ramucirumab in Advanced Hepatocellular Carcinoma and Elevated Alpha-fetoprotein Following Sorafenib: Outcomes by Prior Transarterial Chemoembolisation From Two Randomised, Double-blind, Placebo-controlled Phase 3 Studies (REACH-2 and REACH)

Access the abstract

Yoon-Koo Kang , MD, PhD;

Chia-Jui Yen ;

Peter R. Galle , MD, PhD;

Josep Llovet ;

Eric Assenat ;

Giovanni Brandi ;

Kenta Motomura ;

Takuji Okusaka ;

Mark Karwal ;

Ari Baron ;

Masafumi Ikeda ;

Kun Liang ;

Richard A. Hubner ;

Chunxiao Wang ;

Masatoshi Kudo , MD, PhD;

Ryan Widau ;

Tim Meyer ;

William Schelman ;

Richard S. Finn ;

Andrew Zhu ;

07/31/2019

CIO 2020-22 Durvalumab±Bevacizumab As Adjuvant Therapy In HCC At Risk Of Recurrence After Curative Therapy: EMERALD-2

Peter R. Galle , MD, PhD;

Riccardo Lencioni , MD;

Philip He ;

Jennifer J. Knox ;

Shethah Morgan ;

Jiaqi Fan , MD;

Gordon Cohen ;

Sean Cleary ;

Ann-Lii Cheng , MD, PhD;

Norihiro Kokudo ;

Jian Zhou , MD, PhD;

Joong-Won Park ;

07/23/2021

CIO 2022-33 Atezolizumab + Bevacizumab vs Sorafenib in HCC Patients With Prior Locoregional Therapy: IMbrave150 Exploratory Data

BEST POSTER WINNER Late-breaking abstract / Here, we report post hoc exploratory results of atezo + bev vs sorafenib (sor) in pts who had prior LRT using updated IMbrave150 data with 12 m...

Michel P. Ducreux , MD, PhD;

Sairy Hernandez ;

Amit G. Singal ;

Wendy Verret ;

Allan Nicholas , MD, FACC;

Riad Salem , MD, MBA;

Richard S. Finn ;

Peter R. Galle , MD, PhD;

Andrew Zhu ;

Philippe Merle ;

10/17/2022

CIO 2023-1 Four-year Overall Survival from the HIMALAYA Study of Tremelimumab + Durvalumab in Unresectable Hepatocellular Carcinoma

Purpose: In the primary analysis (data cut-off: 27 August 2021) of the phase 3 HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Re...

Yoon-Koo Kang , MD, PhD;

Charu Gupta , MSc;

Maria Reig , MD, PhD;

Peter R. Galle , MD, PhD;

Alejandra Negro , PhD;

Masatoshi Kudo , MD, PhD;

Bruno Sangro , MD, PhD;

George Tat-Ming Lau , MBBS, FRACP, MD, PhD;

Valeriy Vladimirovich Breder , MD, PhD;

Stephen Lam Chan , MD;

Robin Kate Kelley , MD;

Wattana Sukeepaisarnjaroen , MD;